Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib to resensitize iodine-refractory differentiated thyroid cancer to radioiodine
2015-002269-47Phase 2Unknown
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in thyroid cancer, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival at 12 months. Status: unknown.
02
Drugs
selumetinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on 2015-002269-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002269-47.